Efficacy and Tolerability of Two Novel “Standard of Care” Treatments—Intranasal Esketamine Versus Intravenous Ketamine—for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study

Efficacy and Tolerability of Two Novel “Standard of Care” Treatments—Intranasal Esketamine Versus Intravenous Ketamine—for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study

BackgroundIntravenous (IV) ketamine and intranasal (IN) esketamine have been studied as novel alternatives to manage treatment-resistant depression (TRD). The objective of this observational pilot study is to compare the real-world effectiveness and tolerability of IV ketamin...

Full description

Bibliographic Details
Main Authors:	Gilmar Gutierrez, Joshua Rosenblat, Emily Hawken, Jennifer Swainson, Gustavo Vazquez
Format:	Article
Language:	English
Published:	JMIR Publications 2022-05-01
Series:	JMIR Research Protocols
Online Access:	https://www.researchprotocols.org/2022/5/e34711

Similar Items

Association of intranasal esketamine, a novel ‘standard of care’ treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice
by: Peter Giacobbe, et al.
Published: (2022-09-01)

Esketamine/ketamine for treatment-resistant depression
by: Acioly L.T. Lacerda
Published: (2020-05-01)

The Efficacy and Safety of Intranasal Formulations of Ketamine and Esketamine for the Treatment of Major Depressive Disorder: A Systematic Review
by: Ludivine Boudieu, et al.
Published: (2023-12-01)

The role of intranasal esketamine in treatment-resistant depression
by: A. Fraga, et al.
Published: (2021-04-01)

Effectiveness and Tolerability of Intranasal Esketamine in Treatment-Resistant Depression: Report of Two Clinical Cases
by: A. Mercado-Rodríguez, et al.
Published: (2023-03-01)

The drug liking and craving questionnaire (DLCQ) to evaluate addiction risk for ketamine and esketamine
by: Jay Wang, et al.
Published: (2022-03-01)

Acute Effects of Intravenous Sub-Anesthetic Doses of Ketamine and Intranasal Inhaled Esketamine on Suicidal Ideation: A Systematic Review and Meta-Analysis
by: Chen CC, et al.
Published: (2023-03-01)

How effective are ketamine or esketamine in treatment-resistant depression?
by: N. Veluri, et al.
Published: (2021-04-01)

The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression
by: Maria Pepe, et al.
Published: (2023-10-01)

Case report: Intramuscular ketamine or intranasal esketamine as a treatment in four patients with major depressive disorder and comorbid anorexia nervosa
by: Johanna Louise Keeler, et al.
Published: (2023-05-01)

Intranasal esketamine and the dawn of precision psychiatry
by: Devon Watts, et al.
Published: (2021-07-01)

Acute Effects of Intravenous Sub-Anesthetic Doses of Ketamine and Intranasal Inhaled Esketamine on Suicidal Ideation: A Systematic Review and Meta-Analysis: Letter in Response [Letter]
by: Manu L
Published: (2023-07-01)

Clinical stability after compassionate use of intranasal esketamine in treatment-resistant depression
by: D. Hernandez Huerta, et al.
Published: (2022-06-01)

Acute Effects of Intravenous Sub-Anesthetic Doses of Ketamine and Intranasal Inhaled Esketamine on Suicidal Ideation: A Systematic Review and Meta-Analysis: Letter in Response [Response to Letter]
by: Chen CC, et al.
Published: (2023-07-01)

Comparison of ketamine infusion, intranasal esketamine spray and repetitive Transcranial Magnetic Stimulation (rTMS) for treatment-resistant depression at a suburban tertiary clinic
by: Maria Cristina Davila, et al.
Published: (2022-09-01)

Comparison of the effectiveness of intranasal ketamine compared with intravenous ketamine in controlling pain during cataract surgery
by: Hamidreza Shetabi, et al.
Published: (2022-11-01)

The use of ketamine and esketamine in psychiatry: now and beyond
by: Jose Carlos Appolinario, et al.
Published: (2022-10-01)

Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders
by: Miriam Olivola, et al.
Published: (2022-02-01)

Intranasal esketamine as therapeutic option: a case report of an adolescent with treatment resistant depression
by: Katrin Skala, et al.
Published: (2023-06-01)

Intranasal Esketamine administration in catatonia: a case report.
by: J. Romay, et al.
Published: (2023-03-01)

Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review
by: Enrico Capuzzi, et al.
Published: (2021-08-01)

Patient-reported outcomes on sleep quality and circadian rhythm during treatment with intravenous ketamine for treatment-resistant depression
by: Raymond Yan, et al.
Published: (2024-03-01)

Intranasal esketamine use in bipolar disorder: A case report
by: Courtney Skriptshak, PharmD, et al.
Published: (2021-07-01)

Repeated intravenous esketamine treatment in patients with ECT-resistant major depressive disorder
by: A. Safai Pour, et al.
Published: (2022-12-01)

Analgesic effect of intranasal ketamine in the treatment of chronic cancer pain
by: Secundino González Pardo, et al.
Published: (2022-05-01)

An Update on the Efficacy of Single and Serial Intravenous Ketamine Infusions and Esketamine for Bipolar Depression: A Systematic Review and Meta-Analysis
by: Nicolas A. Nunez, et al.
Published: (2023-12-01)

Esketamine Anesthetizes Mice With a Similar Potency to Racemic Ketamine
by: Xiaofan Ma, et al.
Published: (2023-02-01)

Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review
by: Fabrice Jollant, et al.
Published: (2023-02-01)

The analgesic effect of combined treatment with intranasal S-ketamine and intranasal midazolam compared with morphine patient-controlled analgesia in spinal surgery patients: a pilot study
by: Riediger C, et al.
Published: (2015-02-01)

A survey of drug liking and cravings in patients using sublingual or intranasal ketamine for treatment resistant depression: A preliminary evaluation of real world addictive potential
by: Brittany Chubbs, et al.
Published: (2022-11-01)

Esketamine may be an ideal substitute for ketamine during cochlear function measurement
by: Yufeng Li, et al.
Published: (2021-08-01)

Efficacy and Safety of Intranasal Esketamine in Patients With Treatment-Resistant Depression and Comorbid Chronic Post-traumatic Stress Disorder: Open-Label Single-Arm Pilot Study
by: Maud Rothärmel, et al.
Published: (2022-07-01)

Median effective dose of esketamine for intranasal premedication in children with congenital heart disease
by: Jiajia Huang, et al.
Published: (2023-04-01)

Case report: Intranasal esketamine for severe major depressive disorder with psychotic features
by: Maximilian Carter, et al.
Published: (2022-07-01)

A randomized double-blind trial of intranasal dexmedetomidine versus intranasal esketamine for procedural sedation and analgesia in young children
by: Anna Nikula, et al.
Published: (2024-03-01)

Hype or hope? High placebo response in major depression treatment with ketamine and esketamine: a systematic review and meta-analysis
by: Alexandros Matsingos, et al.
Published: (2024-03-01)

Comparing the analgesic effect of intranasal with intravenous ketamine in isolated orthopedic trauma: A randomized clinical trial
by: Ramin Parvizrad, et al.
Published: (2017-09-01)

Listening to music during intranasal (es)ketamine therapy in patients with treatment-resistant depression correlates with better tolerability and reduced anxiety
by: Johannes Hauser, et al.
Published: (2024-01-01)

Comparing fast-acting interventions for treatment-resistant depression: An explorative study of accelerated HF-rTMS versus intranasal esketamine
by: Mauro Pettorruso, et al.
Published: (2023-07-01)

Pharmacokinetics, absolute bioavailability and tolerability of ketamine after intranasal administration to dexmedetomidine sedated dogs.
by: Lise Vlerick, et al.
Published: (2020-01-01)